Special Issue

Antibiotic Resistance: From the Bench to Patients

Message from the Guest Editors

The emergence of multidrug-resistant bacteria is a serious public health issue which requires global action of an intersectoral nature. As pharmaceutical companies are struggling to keep up with the increase in the resistance trends of various pathogens, the conscious use of the existing antimicrobials is of utmost importance. General practitioners and community pharmacists usually represent the first-line of interaction with healthcare for most of the patients; therefore, they need to act as "gate keepers" while prescribing/dispensing antibiotics. The appropriateness of the healthcare professionals' knowledge-attitudepractice is critical for proper patient education and for attaining change in their attitudes. The purpose of this issue is to present novel results on the epidemiology of various MDR pathogens worldwide, to describe novel diagnostic and point-of-care tests to aid proper antibiotic therapy, interventional studies to improve antimicrobial drug utilization, and various studies reporting on the knowledge, attitude, and practice of healthcare professionals and patients regarding antibiotic resistance.

Guest Editors

Dr. Fernando Albericio

- School of Chemistry, University of KwaZulu-Natal, Durban, South Africa
- 2. Department of Organic Chemistry, University of Barcelona, CIBER-BBN, Barcelona, Spain

Dr. Márió Gajdács

Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary

Deadline for manuscript submissions

closed (31 May 2020)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/31363

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

